RecruitingNot applicableNCT07316478
Stress Management and Mindfulness Intervention for Patients With Sickle Cell Disease
Studying Genetic hemoglobinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pennsylvania
- Principal Investigator
- Melissa G Hunt, PhDUniversity of Pennsylvania
- Intervention
- Stress Management and Mindfulness Intervention for Patients with Sickle Cell Disease(behavioral)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2026
Study locations (1)
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07316478 on ClinicalTrials.govOther trials for Genetic hemoglobinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488091Multi Disciplinary Sickle Cell Disease Obstetrics Care Program in GhanaUniversity of Ghana Medical School
- RECRUITINGNANCT07188766Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive CrisisImam Abdulrahman Bin Faisal University
- RECRUITINGNANCT07090668Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell DiseaseEmory University
- RECRUITINGPHASE1NCT07087262A Phase I Study of SNH-119014 in Healthy VolunteersScinnoHub Pharmaceutical Co., Ltd.
- RECRUITINGNANCT06886477Sickle Cell, Pain and Mediterranean DietUniversity of Illinois at Chicago
- RECRUITINGNANCT06367192School Readiness Intervention for Preschool Children With Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT06735625Pilot Study "AHSP as a Biomarker of Sickle Cell Disease in a Population of Adults and Children"Centre Hospitalier de Saint-Denis
- RECRUITINGPHASE1, PHASE2NCT06144749A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)Hillhurst Biopharmaceuticals, Inc.